

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 18 2002

TECH CENTER 1600/2900

In re application of

Jose V. Torres

Appln. No.: 10/072,084

Filed: February 8, 2002

For: IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF

Attorney Docket No.: 3648.032

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97 and §1.98

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the following documents for the above-identified application, which were cited in the International Search Report. Copies of the documents set forth below and listed on the attached Form PTO-1449 are provided herewith.

1. U.S. Patent No. 5,580,563
2. U.S. Patent No. 6,110,465
3. Meyer, Debra, et. al; Hypervariable Epitope Constructs Representing Variability in Envelope Glycoprotein of SIV Induce a Broad Humoral Immune Response in Rabbits

- and Rhesus Macaques; AIDS Research and Human Retroviruses, 1998, 14.9, pp. 751-760
4. Puntoriero, Giulia, et al.; Towards a Solution for Hepatitis C Virus Hypervariability: Mimotopes of the Hypervariable Region 1 Can Induce Antibodies Cross-Reacting With a Large Number of Viral Variants; The EMBO Journal, 1998, 17.13, pp. 3521-3533
 5. Anderson, David E., et al.; Hypervariable Epitope Constructs As a Means of Accounting for Epitope Variability; Vaccine, 1994, 12.8, pp.736-740
 6. Meyer, Debra and Torres, Jose V.; Hypervariable Epitope Construct: A Synthetic Immunogen That Overcomes MHC Restriction of Antigen Presentation; Molecular Immunology, 1999, 36, pp. 631-637
 7. Nardelli, B., et al.; A Chemically Defined Synthetic Vaccine Model for HIV-1; The Journal of Immunology, 1992, 148.3, pp. 914-920
 8. Prezzi, Caterina, et al.; Selection of Angigenic and Immunogenic Mimics of Hepatitis C Virus Using Sera from Patients; The Journal of Immunology, 1996, 156, pp. 4504-4513
 9. Lenstra, Johannes A., et al.; Isolation of Sequences From a Random-Sequence Expression Library That Mimic Viral Epitopes, Journal of Immunological Methods, 1992, 152, pp. 149-157

10. Carlos, Maria P., et al.; Antibodies From HIV-Positive and AIDS Patients Bind to an HIV Envelope Multivalent Vaccine, Journal of Acquired Immune Deficiency Syndromes, 1999, 22, pp. 317-324
11. Carlos, Maria P., et al.; Immunogenicity of a Vaccine Preparation Representing the Variable Regions of the HIV Type 1 Envelope Glycoprotein, Aids Research and Human Retroviruses, 2000, 16.2, pp. 153-161
12. Jackson, Peter, et al.; Reactivity of Synthetic Peptides representing Selected Sections of Hepatitis C Virus Core and Envelope Proteins With a Panel of Hepatitis C Virus-Seropositive Human Plasma, Journal of Medical Virology, 1997, 61, pp. 67-79
13. Gras-Masse, H., et al.; Synthetic Vaccines and HIV-1 Hypervariability: A "Mixotope" Approach, Peptide Research, 1992, 5.4, pp. 211-216

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date, or (2) before the mailing date of the first Office Action on the merits and, therefore, no Certification Under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to

U.S. PATENT APPLICATION
SERIAL NO.: 10/072,084
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET: 3648.032


antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,



PENDORF & CUTLIFF
P.O. Box 20445
Tampa, Florida 33622-0445
(813) 886-6085



Yaté K. Cutliff
Registration No. 40,577

Date: July 9, 2002

CERTIFICATE OF MAILING AND AUTHORIZATION TO CHARGE

I hereby certify that a copy of the foregoing INFORMATION DISCLOSURE STATEMENT, Form PTO-1449, and thirteen references and attachments thereto for U.S. Application No. 10/072,084 filed February 8, 2002, were deposited in first class U.S. mail, postage prepaid, addressed: Attn: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this the 9th day of July, 2002.

The Commissioner is hereby authorized to charge any additional fees, which may be required at any time during the prosecution of this application without specific authorization, or credit any overpayment, to Deposit Account No. 16-0877.


Yaté K. Cutliff

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)
3648.032

Application Number
10/072,084

Applicant(s)
Jose V. Torres

Filing Date
February 8, 2002

Group Art Unit
1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	5,580,563	12/03/96	Tam	424	197.11	
	2	6,110,465	08/29/00	Bukh et al.	424	189.1	

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

3	Meyer, Debra, et al.; Hypervariable Epitope Constructs Representing Variability in Envelope Glycoprotein of SIV Induce a Broad Humoral Immune Response in Rabbits and Rhesus Macaques; AIDS Research and Human Retroviruses, 1998, 14.9, pp. 751-760
4	Puntoriero, Giulia, et al.; Towards a Solution for Hepatitis C Virus Hypervariability: Mimotopes of the Hypervariable Region 1 Can Induce Antibodies Cross-Reacting With a Large Number of Viral Variants; The EMBO Journal, 1998, 17.13, pp. 3521-3533

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
JUL 18 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

3648.032

Application Number

10/072,084

Applicant(s)

Jose V. Torres

Filing Date

February 8, 2002

Group Art Unit

1646

HC CENTER 1600/2900

JUL 18 2002

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

5

Anderson, David E., et al.; Hypervariable Epitope Constructs As a Means of Accounting for Epitope Variability; Vaccine, 1994, 12.8, pp. 736-740

6

Meyer, Debra and Torres, Jose V.; Hypervariable Epitope Construct: A Synthetic Immunogen That Overcomes MHC Restriction of Antigen Presentation; Molecular Immunology, 1999, 36, pp. 631-637

7

Nardelli, B., et al.; A Chemically Defined Synthetic Vaccine Model for HIV-1; The Journal of Immunology, 1992, 148.3, pp. 914-920

8

Prezzi, Caterina, et al.; Selection of Antigenic and Immunogenic Mimics of Hepatitis C Virus Using Sera from Patients; The Journal of Immunology, 1996, 156, pp. 4504-4513

9

Lenstra, Johannes A., et al.; Isolation of Sequences From a Random-Sequence Expression Library That Mimic Viral Epitopes, Journal of Immunological Methods, 1992, 152, pp. 149-157

10

Carlos, Maria P., et al.; Antibodies From HIV-Positive and AIDS Patients Bind to an HIV Envelope Multivalent Vaccine, Journal of Acquired Immune Deficiency Syndromes, 1999, 22, pp. 317-324

11

Carlos, Maria P., et al.; Immunogenicity of a Vaccine Preparation Representing the Variable Regions of the HIV Type 1 Envelope Glycoprotein, Aids Research and Human Retroviruses, 2000, 16.2, pp. 153-161

12

Jackson, Peter, et al.; Reactivity of Synthetic Peptides Representing Selected Sections of Hepatitis C Virus Core and Envelope Proteins With a Panel of Hepatitis C Virus-Seropositive Human Plasma, Journal of Medical Virology, 1997, 61, pp. 67-79

13

Gras-Masse, H., et al.; Synthetic Vaccines and HIV-1 Hypervariability: A "Mixotope" Approach, Peptide Research, 1992, 5.4, pp. 211-216

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.